NO20050679L - Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging to exhibit intravascular thrombi - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging to exhibit intravascular thrombi

Info

Publication number
NO20050679L
NO20050679L NO20050679A NO20050679A NO20050679L NO 20050679 L NO20050679 L NO 20050679L NO 20050679 A NO20050679 A NO 20050679A NO 20050679 A NO20050679 A NO 20050679A NO 20050679 L NO20050679 L NO 20050679L
Authority
NO
Norway
Prior art keywords
metal complexes
exhibit
magnetic resonance
resonance imaging
contrast agents
Prior art date
Application number
NO20050679A
Other languages
Norwegian (no)
Inventor
Hanns-Joachim Weinmann
Johannes Platzek
Ulrich Niedballa
Bernd Misselwitz
Yoko Kawata
Takishi Yokawa
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20050679L publication Critical patent/NO20050679L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen omhandler anvendelse av perfluoralkyl-inneholdende metallkomplekser som har en kritisk micelledannelseskonsentrasjon på < 10-3 mol/l, en hydrodynamisk micellediameter på (2 Rh) ( 1 nm og en protonrelaksivitet i plasma på (R') > 10 l/mmol's, som et kontrastmiddel brukt i MR- billeddannelse for visualisering av intravaskulære tromber.The invention relates to the use of perfluoroalkyl-containing metal complexes having a critical micelle formation concentration of <10-3 mol / l, a hydrodynamic micelle diameter of (2 Rh) (1 nm and a plasma proton relaxivity of (R ')> 10 l / mmol's). a contrast agent used in MRI imaging to visualize intravascular thrombi.

NO20050679A 2002-07-10 2005-02-09 Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging to exhibit intravascular thrombi NO20050679L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10231799A DE10231799B4 (en) 2002-07-10 2002-07-10 Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for the presentation of intravascular thrombi
PCT/EP2003/007274 WO2004006965A2 (en) 2002-07-10 2003-07-05 Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging for representing intravascular thrombi

Publications (1)

Publication Number Publication Date
NO20050679L true NO20050679L (en) 2005-04-08

Family

ID=30009959

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050679A NO20050679L (en) 2002-07-10 2005-02-09 Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging to exhibit intravascular thrombi

Country Status (23)

Country Link
EP (1) EP1519756B1 (en)
JP (1) JP2005532404A (en)
CN (1) CN1668338A (en)
AR (1) AR041187A1 (en)
AT (1) ATE361103T1 (en)
AU (2) AU2003281146A1 (en)
BR (1) BR0312552A (en)
CA (1) CA2491933A1 (en)
DE (2) DE10231799B4 (en)
DK (1) DK1519756T3 (en)
ES (1) ES2285143T3 (en)
IL (1) IL165889A0 (en)
MX (1) MXPA04012950A (en)
NO (1) NO20050679L (en)
PE (1) PE20040656A1 (en)
PL (1) PL374027A1 (en)
PT (1) PT1519756E (en)
RS (1) RS20050020A (en)
RU (1) RU2328310C2 (en)
TW (1) TW200413008A (en)
UA (1) UA79294C2 (en)
WO (2) WO2004006979A2 (en)
ZA (1) ZA200501172B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006021495A1 (en) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Use of metal chelate containing perfluorinated alkyl-residue, chelator-residue and metal ion equivalent to the atomic number, for the production of diagnostic agent for representation of amyloid-containing plaques
BRPI0922839A2 (en) * 2008-12-05 2019-09-03 Molecular Insight Pharm Inc ca-ix-specific radiopharmaceuticals for cancer treatment and imaging.
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN107445911B (en) * 2017-06-19 2019-07-05 南京科技职业学院 Two core mr contrast agents containing gadolinium of one kind and its preparation and application
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
CN109867635A (en) * 2019-02-14 2019-06-11 华东师范大学 A kind of T1 type micella magnetic resonance imaging contrast and preparation method thereof
EP4059925A1 (en) 2021-03-15 2022-09-21 Bayer Aktiengesellschaft New contrast agent for use in magnetic resonance imaging
EP4335840A1 (en) 2022-09-09 2024-03-13 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
EP4335462A1 (en) 2022-09-09 2024-03-13 Bayer AG Contrast agents for use in diagnostic computed tomography imaging

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571498A (en) * 1994-06-02 1996-11-05 Hemagen/Pfc Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI).
DE19603033A1 (en) * 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
WO1998016256A1 (en) * 1996-10-16 1998-04-23 The Burnham Institute Magnetic resonance imaging of thrombi
DE19729013A1 (en) * 1997-07-03 1999-02-04 Schering Ag Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
DE19914101C1 (en) * 1999-03-22 2000-10-12 Schering Ag Perfluoroalkylamides, their preparation and their use in diagnostics
EA200200220A1 (en) * 1999-07-29 2002-08-29 Эпикс Медикал, Инк. AIMING MULTIMERAL VISUALIZING AGENTS WITH A MULTI-CUSCLE BINDING MECHANISM
DE19948651B4 (en) * 1999-09-29 2006-10-05 Schering Ag Galenic formulations containing para and diamagnetic perfluorinated compounds, their preparation and use
US6565828B2 (en) * 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
DE10040380B4 (en) * 2000-08-11 2006-03-09 Schering Ag MRI contrast agent for visualization of plaque, lymph nodes, infarcted and necrotic tissue or both necrosis and tumors, comprising perfluoroalkylated metal complex having specific micelle forming properties
DE10040858C2 (en) * 2000-08-11 2003-12-18 Schering Ag Perfluoroalkyl-containing complexes with polar residues, process for their preparation and their use
DE10040381C1 (en) * 2000-08-11 2002-06-06 Schering Ag Perfluoroalkyl-containing complexes with sugar residues, process for their preparation and their use
DE10066210B4 (en) * 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for plaque imaging

Also Published As

Publication number Publication date
DE50307180D1 (en) 2007-06-14
ATE361103T1 (en) 2007-05-15
UA79294C2 (en) 2007-06-11
WO2004006979A2 (en) 2004-01-22
AU2003281150A1 (en) 2004-02-02
DE10231799B4 (en) 2006-10-05
ES2285143T3 (en) 2007-11-16
PT1519756E (en) 2007-07-12
DE10231799A1 (en) 2004-02-12
CA2491933A1 (en) 2004-01-22
TW200413008A (en) 2004-08-01
DK1519756T3 (en) 2007-08-13
AR041187A1 (en) 2005-05-04
RU2328310C2 (en) 2008-07-10
PE20040656A1 (en) 2004-12-01
RS20050020A (en) 2007-08-03
IL165889A0 (en) 2006-01-15
JP2005532404A (en) 2005-10-27
ZA200501172B (en) 2006-04-26
RU2005103598A (en) 2005-11-20
WO2004006965A2 (en) 2004-01-22
MXPA04012950A (en) 2005-05-16
AU2003281146A1 (en) 2004-02-02
CN1668338A (en) 2005-09-14
PL374027A1 (en) 2005-09-19
WO2004006965A3 (en) 2004-07-15
EP1519756B1 (en) 2007-05-02
BR0312552A (en) 2005-04-26
EP1519756A2 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
NO20050679L (en) Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging to exhibit intravascular thrombi
Gupta et al. Applications for transition-metal chemistry in contrast-enhanced magnetic resonance imaging
Toth et al. Relaxivity of gadolinium (III) complexes: theory and mechanism
Troughton et al. Synthesis and evaluation of a high relaxivity manganese (II)-based MRI contrast agent
Caravan et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates
Caravan et al. The Gd3+ complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities
Aime et al. Prototropic vs whole water exchange contributions to the solvent relaxation enhancement in the aqueous solution of a cationic Gd3+ macrocyclic complex
Louca et al. MR urography in the diagnosis of urinary tract obstruction
IS2127B (en) Metallic constituents containing perfluoroalkyl and their use in magnetic resonance imaging
IL180896A0 (en) Method of tumour imaging
MX2023010737A (en) New contrast agent for use in magnetic resonance imaging.
WO2000030688A3 (en) Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as mri contrast agents
Aime et al. Exploiting the Proton Exchange as an Additional Route to Enhance the Relaxivity of Paramagnetic MRI Contrast Agents
YU10603A (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumors and necroses
EP1258252A4 (en) Integrin expression inhibitors
NO991688D0 (en) Manageable compositions and methods for magnetic resonance imaging
Bond et al. Exploring inner-sphere water interactions of Fe (II) and Co (II) complexes of 12-membered macrocycles to develop CEST MRI probes
Boros et al. Gd (DOTAlaP): exploring the boundaries of fast water exchange in gadolinium-based magnetic resonance imaging contrast agents
DK0700393T3 (en) Flourous, macrocyclic metal complexes
ITMI20011708A0 (en) CONJUGATES OF PEPTIDES, THEIR DERIVATIVES WITH METAL COMPLEXES AND USE FOR DIAGNOSTIC INVESTIGATION THROUGH MAGNETIC RESONANCE IMAGING (M
Brahmadevara et al. Evidence against β3‐adrenoceptors or low affinity state of β1‐adrenoceptors mediating relaxation in rat isolated aorta
Wiener et al. Bifunctional chelates optimized for molecular MRI
Jocher et al. Optimized Relaxivity and Stability of [Gd (H (2, 2)-1, 2-HOPO)(H2O)]-for Use as an MRI Contrast Agent1
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
David et al. Guanidinium derivatives act as high affinity antagonists of Na+ ions in occlusion sites of Na+, K (+)-ATPase.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application